Meenakshi Anurag
TitleCited byYear
Crowd sourcing a new paradigm for interactome driven drug target identification in Mycobacterium tuberculosis
R Vashisht, AK Mondal, A Jain, A Shah, P Vishnoi, P Priyadarshini, ...
PloS one 7 (7), e39808, 2012
Unraveling the potential of intrinsically disordered proteins as drug targets: application to Mycobacterium tuberculosis
M Anurag, D Dash
Molecular BioSystems 5 (12), 1752-1757, 2009
A web server for predicting inhibitors against bacterial target GlmU protein
D Singla, M Anurag, D Dash, GPS Raghava
BMC pharmacology 11 (1), 5, 2011
The prognostic effects of somatic mutations in ER-positive breast cancer
OL Griffith, NC Spies, M Anurag, M Griffith, J Luo, D Tu, B Yeo, J Kunisaki, ...
Nature communications 9 (1), 1-16, 2018
Loss of MutL Disrupts Chk2-dependent Cell Cycle Control Through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Cancer Discovery, 2017
Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers
M Anurag, N Punturi, J Hoog, MN Bainbridge, MJ Ellis, S Haricharan
Clinical Cancer Research 24 (19), 4887-4899, 2018
Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer
JT Lei, J Shao, J Zhang, M Iglesia, DW Chan, J Cao, M Anurag, P Singh, ...
Cell reports 24 (6), 1434-1444. e7, 2018
Amplification of TLK2 Induces Genomic Instability via Impairing the G2–M Checkpoint
JA Kim, M Anurag, J Veeraraghavan, R Schiff, K Li, XS Wang
Molecular Cancer Research 14 (10), 920-927, 2016
Location of disorder in coiled coil proteins is influenced by its biological role and subcellular localization: a GO-based study on human proteome
M Anurag, GP Singh, D Dash
Molecular BioSystems 8 (1), 346-352, 2012
DNA damage repair defects as a new class of endocrine treatment resistance driver
M Anurag, MJ Ellis, S Haricharan
Oncotarget 9 (91), 36252, 2018
Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort
AS Cheng, SCY Leung, D Gao, S Burugu, M Anurag, MJ Ellis, TO Nielsen
Breast cancer research and treatment 179 (1), 3-10, 2020
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance)
M Anurag, M Zhu, C Huang, S Vasaikar, J Wang, J Hoog, S Burugu, ...
JNCI: Journal of the National Cancer Institute, 2019
Abstract GS2-02: direct regulation of estrogen receptor-α (ER) transcriptional activity by NF1
EC Chang, Z Zheng, L Philip, C Burcu, J Lei, P Singh, M Anurag, D Chan, ...
Cancer Research 78 (4 Supplement), GS2-02-GS2-02, 2018
Abstract P4-04-01: Loss of mismatch repair predicts resistance to endocrine therapy and sensitivity to CDK4/6 inhibitors in ER+ breast cancer
S Haricharan, N Punturi, P Singh, KR Holloway, M Anurag, J Schmelz, ...
Cancer Research 78 (4 Supplement), P4-04-01-P4-04-01, 2018
Abstract PD8-03: ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer
JT Lei, J Shao, J Zhang, M Iglesia, DW Chan, J Cao, M Anurag, P Singh, ...
Cancer Research 78 (4 Supplement), PD8-03-PD8-03, 2018
Abstract GS2-05: Microscaled proteogenomic methods for precision oncology
S Satpathy, E Jaehnig, K Karsten, BJ Kim, A Saltzman, D Chan, ...
Cancer Research 80 (4 Supplement), GS2-05-GS2-05, 2020
Proteogenomic Characterization of Endometrial Carcinoma
Y Dou, EA Kawaler, DC Zhou, MA Gritsenko, C Huang, L Blumenberg, ...
Cell, 2020
Microscaled proteogenomic methods for precision oncology
S Satpathy, EJ Jaehnig, K Krug, BJ Kim, AB Saltzman, DW Chan, ...
Nature Communications 11 (1), 1-16, 2020
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
DJ Clark, SM Dhanasekaran, F Petralia, J Pan, X Song, Y Hu, ...
Cell 180 (1), 207, 2020
CDK4/6 inhibitor biomarker research: are we barking up the wrong tree?
M Anurag, S Haricharan, MJ Ellis
Clinical Cancer Research 26 (1), 3-5, 2020
The system can't perform the operation now. Try again later.
Articles 1–20